Poseida Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of PSTX for the last quarter is 25.00 M USD, and it's 167.27% higher compared to the previous quarter. The net income of Q4 23 is -25.35 M USD.